



October 2009

Dear Valued Customer,

In our previous customer letters in February and September of this year concerning the HOVON 82 study, we committed to update you as new information related to the study became available. Pursuant to the presentation of the HOVON 82 abstract at the AABB meeting on Sunday, October 25th, we would like to provide you with an update.

Cerus' primary interest has been the full disclosure of all the study data and the statistical analyses. We are pleased that the interim data is now available, so that the transfusion medicine community can assess the import of this study relative to the extensive clinical experience that already exists for INTERCEPT platelets.

The following is a brief summary of the presentation:

- As expected, there were CCI differences between INTERCEPT and control platelets, consistent with those seen in previous studies.
- Beyond what was disclosed in the HOVON 82 AABB abstract, detailed data regarding bleeding were not presented, and the authors could not conclude whether any observed qualitative or quantitative differences were related to INTERCEPT treatment.
- The study had difficulty in maintaining study patients on-protocol. With more than a third of the platelet transfusions in the INTERCEPT arm given off-protocol, the statistical analysis of the data proved challenging.

After the presentation, questions from the audience explored the criteria for bleeding assessments, the utility of CCI as an indicator of clinical efficacy, the statistical power of the interim and future analyses, and comparisons to the SPRINT trial and routine use experience with INTERCEPT platelets.

The full analysis of the data will likely take some time to be published in a peer-reviewed journal. We expect that all of the confounding variables that may have impacted the outcome of the HOVON 82 study will be fully described in that publication. We appreciated the frank discussion by the presenter of the challenges in the conduct and analysis of the HOVON 82 study.

We remain confident in our product, and thank you for choosing INTERCEPT as your pathogen inactivation method.

Please feel free to contact us at any time with your questions on this matter.

Yours sincerely,

Cerus BV